IMPORTANT INVESTOR ALERT: Marcus & Boxerman Announces an Ongoing Investigation of Amicus Therapeutics, Inc. and Encourages Investors to Contact the Firm

CHICAGO--(BUSINESS WIRE)-- Marcus & Boxerman announces that it is investigating claims of potential misrepresentations by Amicus Therapeutics, Inc. (“Amicus” or the “Company”) (Nasdaq: FOLD). The investigation will focus on whether the Company and its officers violated securities laws by issuing misleading statements and/or failing to disclose material information to investors.

To participate in this class action lawsuit, please contact Michael Boxerman, Esquire, of Marcus & Boxerman, at 312-216-2730, or via email at [email protected].

On October 2, 2015, Amicus announced that after meeting with FDA officials, the Company does not anticipate being able to submit a new drug application (NDA) for migalastat, the company's Fabry disease treatment, by the end of the year.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151201006952/en/

Marcus & Boxerman
Michael Boxerman, Esq., 312-216-2730
[email protected]
Facsimile: 312-216-2720

Source: Marcus & Boxerman

You May Also Be Interested In

• Amicus Therapeutics (FOLD) PT Lowered to $14 at BofA Securities
• Jorie AI Webinar - Thursday, April 18th, 2024, 'Jorie AI: Redundancy in the Wake of Healthcare’s Worst Ever Security Breach Webinar'
• BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn